DEA relaxes rules for cannabis drug, descheduling it completely
On April 6th the DEA announced it was relaxing the rules on Epidiolex, making it no longer a scheduled substance. Epidiolex, derived from marijuana, is the only
The FDA recently admitted to pushing the corporate pharmaceutical agenda
Congress held a committee hearing to discuss several proposals involving cannabis, and the FDA was there to be questioned. An answer given stuck out amongst the vast amount of situations and questions posed to the